Current treatment options for hemangiomas, such as propranolol, steroids and interferon, all
have the potential for significantly harmful side effects. The purpose of this study is to
identify potential biomarkers that can be used to design clinical trials and accelerate the
delivery of new treatment alternatives to children with hemangiomas.